Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

Model scores of the 29,894 trials active now.

Model score 31% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-06-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tumorradiationcellcancertumors
  Phrases that lowered it: participantdrugadministrationmonthabuse
• Sponsor's past termination rate: 14.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 15.5% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Maximum age: 21 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 16 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 77.8% (lowers risk) · Drug's FDA history
• Primary purpose: supportive care (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 8745 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors NCT00566852 · started 2008 · scored riskier than 93% of active trials completed
• Memantine for Recurrent Glioblastoma NCT01260467 · started 2010 · scored riskier than 98% of active trials terminated
• Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor NCT01381718 · started 2011 · scored riskier than 90% of active trials completed
• A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM) NCT01372449 · started 2011 · scored riskier than 34% of active trials completed
• Testing Ramipril to Prevent Memory Loss in People With Glioblastoma NCT03475186 · started 2019 · scored riskier than 98% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.